Posted by Michael Wonder on 29 Jun 2023
Amicus Therapeutics announces approval and launch of new Pompe disease therapy in the European Union
27 June 2023 - Pombiliti (cipaglucosidase alfa) and Opfolda (miglustat) now approved in the European Union for adults with late-onset Pompe disease.
Amicus Therapeutics today announced that the European Commission has granted approval for Opfolda (miglustat) 65mg capsules, an enzyme stabiliser of cipaglucosidase alfa, a long-term enzyme replacement therapy for adults with late-onset Pompe disease.
